Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversity
AUTOR(ES)
Zingales, Bianca, Miles, Michael A, Moraes, Carolina B, Luquetti, Alejandro, Guhl, Felipe, Schijman, Alejandro G, Ribeiro, Isabela
FONTE
Mem. Inst. Oswaldo Cruz
DATA DE PUBLICAÇÃO
22/08/2014
RESUMO
This opinion piece presents an approach to standardisation of an important aspect of Chagas disease drug discovery and development: selecting Trypanosoma cruzi strains for in vitro screening. We discuss the rationale for strain selection representing T. cruzi diversity and provide recommendations on the preferred parasite stage for drug discovery, T. cruzi discrete typing units to include in the panel of strains and the number of strains/clones for primary screens and lead compounds. We also consider experimental approaches for in vitro drug assays. The Figure illustrates the current Chagas disease drug-discovery and development landscape.
Documentos Relacionados
- Identificação de novos inibidores da enzima cruzaína de Trypanosoma cruzi candidatos a fármacos contra a doença de Chagas
- Inositol metabolism in Trypanosoma cruzi: potential target for chemotherapy against Chagas' disease
- Insect vectors of Chagas disease (Trypanosoma cruzi) in Northeastern Brazil
- Looking for combination of benznidazole and Trypanosoma cruzi-triosephosphate isomerase inhibitors for Chagas disease treatment
- PCR-based detection of Trypanosoma cruzi useful for specific diagnosis of human Chagas' disease.
